Literature DB >> 17240289

Huntington's disease.

Francis O Walker1.   

Abstract

Huntington's disease is an autosomal-dominant, progressive neurodegenerative disorder with a distinct phenotype, including chorea and dystonia, incoordination, cognitive decline, and behavioural difficulties. Typically, onset of symptoms is in middle-age after affected individuals have had children, but the disorder can manifest at any time between infancy and senescence. The mutant protein in Huntington's disease--huntingtin--results from an expanded CAG repeat leading to a polyglutamine strand of variable length at the N-terminus. Evidence suggests that this tail confers a toxic gain of function. The precise pathophysiological mechanisms of Huntington's disease are poorly understood, but research in transgenic animal models of the disorder is providing insight into causative factors and potential treatments.

Entities:  

Mesh:

Year:  2007        PMID: 17240289     DOI: 10.1016/S0140-6736(07)60111-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  621 in total

1.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

2.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 3.  Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases.

Authors:  Daniel W Neef; Alex M Jaeger; Dennis J Thiele
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

4.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

Review 5.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 6.  The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.

Authors:  Prashant Deshmukh; Sruthi Unni; Gopinatha Krishnappa; Balasundaram Padmanabhan
Journal:  Biophys Rev       Date:  2016-12-06

Review 7.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

8.  Early Detection of Apathetic Phenotypes in Huntington's Disease Knock-in Mice Using Open Source Tools.

Authors:  Shawn Minnig; Robert M Bragg; Hardeep S Tiwana; Wes T Solem; William S Hovander; Eva-Mari S Vik; Madeline Hamilton; Samuel R W Legg; Dominic D Shuttleworth; Sydney R Coffey; Jeffrey P Cantle; Jeffrey B Carroll
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

9.  Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.

Authors:  Udo Rüb; Matthias Hentschel; Katharina Stratmann; Ewout Brunt; Helmut Heinsen; Kay Seidel; Mohamed Bouzrou; Georg Auburger; Henry Paulson; Jean-Paul Vonsattel; Herwig Lange; Horst-Werner Korf; Wilfred den Dunnen
Journal:  Brain Pathol       Date:  2014-03-03       Impact factor: 6.508

10.  'You don't get told anything, they don't do anything and nothing changes'. Medicine as a resource and constraint in progressive ataxia.

Authors:  Gavin Daker-White; Helen Kingston; Katherine Payne; Julie Greenfield; John Ealing; Caroline Sanders
Journal:  Health Expect       Date:  2012-10-24       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.